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Despite the huge progress in the understanding of the
pathomechanism of thyroid orbitopathy (OT) done during
recent years this extrathyroidal manifestation of Graves’
disease still remains one of the most complex problems of
clinical endocrinology. The outcome of the management
is not satisfying neither for patient nor for physicians.
Some likelihood of the improvement of the results may be
expected from innovative treatment options basing on the
progress in understanding of mechanisms of autoimmu-
nity and inflammation. On the other hand an effort must
be done for the progress in the existing treatment regimes.
Glucocorticoids have been used in the treatment of
severe OT for over 50 years but irrespectively of therapeu-
tic regime any improvement in eye changes may be
achieved only in ca. 70% of patients. Numerous schemes
of glucocorticoid use should be validated, optimized and
meet an individual approach as well as adhere to the local
capabilities.
The common adjuvant treatment with selenium in
Graves’ disease patients may prevent from a development
of eye symptoms and possibly will improve the quality of
life.
The mode of management of hyperthyroidism has an
influence on OT. Medical and surgical therapy seem not
to deteriorate the course of OT while radioiodine therapy
may worsen eye symptoms. OT patients at high risk
should get the preventive glucocorticoid treatment.
The access to a surgical treatment procedures as orbital
decompression and rehabilitative surgery must be assured
for OT patients and techniques of surgical procedures
should be developed.
The results of anticytokine therapy are promising and
the progress in this field may be expected while the value
of newly developed TSH receptor blocking molecules
needs further observations.
The frequency of circulating CD40(+) fibrocytes is
markedly increased in patients with OT, suggesting that
this receptor might represent a therapeutic target for OT.
An increase in a local steroidogenesis documented
within orbital tissues in an active phase of OT rises the
idea of the use of 11b hydroxysteroid dehydrogenase-1
inhibitors in OT patients. These drugs are under intensive
clinical investigation for the treatment of type 2 diabetics.
Since recommendations basing on EBM according to
the pivotal problems of the management OT are still lack-
ing, the system of care for OT patients should be based on
centres of excellence with proper experience and multidis-
ciplinary approach.
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